BCL2L1 and colorectal carcinoma: Thus, we independently tested a panel of 17 well-characterized human CRC cell lines with small molecules6 that selectively and potently inhibit BCL2 (venetoclax), BCLxL (A1331852), or MCL1 (S64845).